Clinical Trials Logo
  1. Home
  2. Immune Thrombocytopenic Purpura
  3. NCT01672151

Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia — ITP  

Immune Thrombocytopenic Purpura Clinical Trial

Official title:
Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia

Clinical Trial Summary

The aim of our study is to evaluate the efficacy of rapamycin with Refractory Immune Thrombocytopenic Purpura (RITP) and explore the further mechanism.

Clinical Trial Description

Rapamycin, an immunosuppressive drug, is widely used to prevent allograft rejection and autoimmune diseases. Many studies have shown that the drug contributes to the expansion of regulatory T cells and preserves the highly suppressive function of autoreactive T cells. Patients with RITP often display a decreased proportion of regulatory T cells by flow cytometer, therefore, the investigators will examine the efficacy of rapamycin in RITP patients. ;

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01672151
Study type Observational
Source First Affiliated Hospital of Suzhou Medical College
Contact
Status Completed
Phase N/A
Start date November 2011
Completion date August 2012
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT01255332 - Helicobacter Pylori Immune Thrombocytopenic Purpura Phase 2
Completed NCT02077192 - Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) Phase 3
Completed NCT01719692 - Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia N/A
Completed NCT01621204 - A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients Phase 3
Completed NCT01730352 - Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients Phase 2/Phase 3
Completed NCT01713855 - Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura N/A
Not yet recruiting NCT05093257 - Study of T Cells and Natural Killer Cells Expression in Patients With Immune Thrombocytopenic Purpura
Completed NCT01390649 - A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Phase 4
Completed NCT01439321 - Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim N/A
Completed NCT00774202 - Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP Phase 2/Phase 3
Completed NCT02273960 - Study to Evaluate Safety and Efficacy in Adult Subjects With ITP Phase 1/Phase 2
Not yet recruiting NCT05585944 - " Effect of Single-nucleotide Polymorphism of CD40 Gene rs1883832 C/T on the Risk of Immune Thrombocytopenic Purpura " N/A
Recruiting NCT03177629 - H. Pylori Eradication for Moderate ITP Phase 3
Not yet recruiting NCT05835050 - Assessment of Serum interleukin10 Level in Patients With Immune Thrombocytopenic Purpura at Sohag University Hospital N/A
Active, not recruiting NCT03395210 - A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP) Phase 2
Completed NCT00621894 - Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation Phase 2
Not yet recruiting NCT06444477 - Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer
Completed NCT01652599 - Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT Phase 2
Completed NCT00426270 - Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults Phase 3
Completed NCT02085993 - Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training N/A